Falcarindiol Enhances Cisplatin Chemosensitivity of Hepatocellular Carcinoma via Down-Regulating the STAT3-Modulated PTTG1 Pathway

被引:13
|
作者
Hong, Han [1 ]
Jin, Zhengkang [1 ]
Qian, Tao [2 ]
Xu, Xiaoyong [1 ]
Zhu, Xiang [1 ]
Fei, Qiang [1 ]
Yang, Jiamei [3 ]
Sui, Chengjun [3 ]
Xu, Minhui [1 ]
机构
[1] Nanjing Med Univ, Dept Hepatopancreatobiliary Surg, Affiliated Suzhou Hosp, Suzhou, Peoples R China
[2] Nanjing Univ Chinese Med, Dept Gen Surg, Affiliated Hosp Integrated Tradit Chinese & Weste, Nanjing, Peoples R China
[3] Shanghai Eastern Hepatobiliary Surg Hosp, Dept Special Treatment & Liver Transplantat, Shanghai, Peoples R China
来源
FRONTIERS IN PHARMACOLOGY | 2021年 / 12卷
基金
上海市自然科学基金;
关键词
falcarindiol; hepatocellular carcinoma; cisplatin chemosensitivity; stat3; PTTG1; TUMOR TRANSFORMING GENE-1; CANCER; CELLS; INFLAMMATION; REPAIR; POLYACETYLENES; CHEMOTHERAPY; SUPPRESSION; PROGRESSION; SURVIVAL;
D O I
10.3389/fphar.2021.656697
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hepatocellular carcinoma (HCC) is the most frequent primary liver malignancy globally and the third leading cause of cancer-related death. Chemotherapy is one of the main methods in treating HCC, while recent studies have found that the resistance of HCC to chemotherapeutic drugs reduces the efficacy of the chemotherapy. Falcarindiol (FAD) is a cytotoxic and anti-inflammatory polyacetylenic oxylipin found in food plants of the carrot family (Apiaceae), while its role in HCC remains to be explored. Here, HCC cells (Huh7 and LM3) were treated with FAD at different doses. Cell proliferation was tested by the cell counting kit-8 (CCK-8) method and colony formation assay, while the apoptosis was monitored by flow cytometry. The profiles of apoptosis-related proteins (Bax, bcl2, and Caspase-3), DNA repair proteins (Rad51, BRCA1, and MDC1), and the signal transducer and activator of transcription 3 (STAT3)/Pituitary Tumor Transforming Gene 1 (PTTG1) were verified by western blot (WB) or quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The interaction between STAT3 and PTTG1 was verified by immunoprecipitation (IP). In addition, a xenograft tumor model was constructed in mice to explore the anti-tumor effects of FAD in vivo, and immunohistochemistry (IHC) was performed to count the number of Ki67-stained cells. As a result, FAD inhibited HCC cell proliferation and DNA repair, facilitated their apoptosis, and also enhanced cisplatin (DDP) chemosensitivity. The Combination Index (CI) evaluation showed that FAD and DDP had synergistic effects in repressing HCC cell proliferation. Besides, FAD dampened the STAT3/PTTG1 pathway expression. Further studies revealed that inhibiting STAT3 enhanced the inhibitive effect of FAD on HCC cells, whereas overexpressing PTTG1 attenuated the anti-tumor effect of FAD. Overall, our study illustrated that FAD is a potential anticancer drug and strengthens the chemosensitivity of HCC cells to DDP by inhibiting the STAT3/PTTG1 pathway.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] microRNA-206 prevents hepatocellular carcinoma growth and metastasis via down-regulating CREB5 and inhibiting the PI3K/AKT signaling pathway
    Chi, Yuan
    Gong, Zheng
    Xin, He
    Wang, Ziwen
    Liu, Zhaoyu
    CELL CYCLE, 2022, 21 (24) : 2651 - 2663
  • [22] MicroRNA-26a Inhibits Angiogenesis by Down-Regulating VEGFA through the PIK3C2α/Akt/HIF-1α Pathway in Hepatocellular Carcinoma
    Chai, Zong-Tao
    Kong, Jian
    Zhu, Xiao-Dong
    Zhang, Yuan-Yuan
    Lu, Lu
    Zhou, Jia-Min
    Wang, Long-Rong
    Zhang, Ke-Zhi
    Zhang, Qiang-Bo
    Ao, Jian-Yang
    Wang, Miao
    Wu, Wei-Zhong
    Wang, Lu
    Tang, Zhao-You
    Sun, Hui-Chuan
    PLOS ONE, 2013, 8 (10):
  • [23] Niclosamide Inhibits Cell Growth and Enhances Drug Sensitivity of Hepatocellular Carcinoma Cells via STAT3 Signaling Pathway
    Wang, Chengzhi
    Zhou, Xiaoqing
    Xu, Hongjuan
    Shi, Xiaqing
    Zhao, Jinfeng
    Yang, Manyi
    Zhang, Lihua
    Jin, Xin
    Hu, Yu
    Li, Xia
    Xiao, Xiangcheng
    Liao, Mingmei
    JOURNAL OF CANCER, 2018, 9 (22): : 4150 - 4155
  • [24] DACH1 inhibits nuclear localization of β-catenin via down-regulating EGFR/ERK/FoxM1 axis in hepatocellular carcinoma cells
    Zhu, Hongbin
    Zhu, Hongbin
    Wang, Dongxu
    He, Yuzhuo
    Ma, Longteng
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 18 - 18
  • [25] DACH1 inhibits nuclear localization of β-catenin via down-regulating EGFR/ERK/FoxM1 axis in hepatocellular carcinoma cells
    Zhu, Hongbin
    Zhu, Hongbin
    Wang, Dongxu
    He, Yuzhuo
    Ma, Longteng
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 18 - 18
  • [26] Triterpenoids principle of Wedelia calendulacea attenuated diethynitrosamine-induced hepatocellular carcinoma via down-regulating oxidative stress, inflammation and pathology via NF-kB pathway
    Amita Verma
    Deepika Singh
    Firoz Anwar
    Prakash Chandra Bhatt
    Fahad Al-Abbasi
    Vikas Kumar
    Inflammopharmacology, 2018, 26 : 133 - 146
  • [27] Triterpenoids principle of Wedelia calendulacea attenuated diethynitrosamine-induced hepatocellular carcinoma via down-regulating oxidative stress, inflammation and pathology via NF-kB pathway
    Verma, Amita
    Singh, Deepika
    Anwar, Firoz
    Bhatt, Prakash Chandra
    Al-Abbasi, Fahad
    Kumar, Vikas
    INFLAMMOPHARMACOLOGY, 2018, 26 (01) : 133 - 146
  • [28] Curcumin combined with glycyrrhetinic acid inhibits the development of hepatocellular carcinoma cells by down-regulating the PTEN/PI3K/AKT signalling pathway
    Chang, Mingxiang
    Wu, Meimei
    Li, Hanmin
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2017, 9 (12): : 5567 - 5575
  • [29] Kanglaite enhances the efficacy of cisplatin in suppression of hepatocellular carcinoma via inhibiting CKLF1 mediated NF-κB pathway and regulating transporter mediated drug efflux
    Chen, Chen
    Ai, Qi-di
    Wei, Yu-hui
    JOURNAL OF ETHNOPHARMACOLOGY, 2021, 264
  • [30] Aspirin enhances IFN-α-induced growth inhibition and apoptosis of hepatocellular carcinoma via JAK1/STAT1 pathway
    Li, T.
    Dong, Z-R
    Guo, Z-Y
    Wang, C-H
    Tang, Z-Y
    Qu, S-F
    Chen, Z-T
    Li, X-W
    Zhi, X-T
    CANCER GENE THERAPY, 2013, 20 (06) : 366 - 374